655 Elizabeth Street
Melbourne, VIC 3000
Australia
61 3 9389 1911
https://www.csl.com.au
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 32 698
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Paul F. McKenzie Ph.D. | MD, CEO & Executive Director | 4,37M | S.O. | 1966 |
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 2,05M | S.O. | 1965 |
Mr. Andy Schmeltz | Executive Vice President of CSL Behring Business Unit | 1,48M | S.O. | 1971 |
Mr. Mark Dehring | Head of Investor Relations | S.O. | S.O. | S.O. |
Mr. Gregory Boss B.S., BS(Hons), J.D. | Executive VP of Legal & General Counsel | 1,1M | S.O. | 1961 |
Christina Hickie | Senior Manager of Communications | S.O. | S.O. | S.O. |
Ms. Roanne Parry | Chief Human Resources Officer | S.O. | S.O. | S.O. |
Dr. Karen Etchberger | Executive Vice President of Quality & Business Services | 1,03M | S.O. | 1958 |
Ms. Jemimah Brennan | Head of Communications - Asia Pacific | S.O. | S.O. | S.O. |
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. | Senior Vice President of Research | S.O. | S.O. | 1962 |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
L’ISS Governance QualityScore de CSL Limited en date du 28 août 2024 est 2. Les scores principaux sont Audit : 4; Société : 4; Droits des actionnaires : 1; Compensation : 4.